CD8A and neoplasm: Although this represents an intriguing observation, the specific phenotype of CD4+ subtypes associated with beneficial outcomes is not known, hence, it is unclear whether the productive benefits of CD4+ T cells in manufacturing or downstream anti-tumor responses in vivo stem from providing help to CD8+ T cells, versus direct anti-tumor effector functions.